Clarivate™

Find known drug-drug interactions for your drug

Cortellis Drug Discovery Intelligence

In this guide you'll learn how to quickly assess the interactions around your drug of interest. Use case: you are designing a clinical study and need to be aware of reported interactions with your drug.

1. Use **Quick Search** to search for your drug of interest (e.g. Rivaroxaban) in the Drug-Drug interactions knowledge area.

2. In the results page, you will find a table that lists all the drug-drug interactions that have been reported for your drug. Within the table, you can sort your results as needed by using the arrows on the column headers, for instance by **Prescription**.

E indicates the outcome is supported by experimental results. A lack of **E** indicates the outcome is anticipated but there is no direct observation reported.

3. Click on **View record** to know the details behind a specific interaction. In the example below, Verapamil hydrochloride inhibits ABCB1 (isoform 1) and CYP3A4 (isoform 1) [*Protein/Action*], causing increased pharmacokinetic exposure [*Outcome*] of Rivaroxaban [*Evaluated Entity*]. This can result in elevated prothrombin time and bleeding [*Adverse Events*]. For this reason, there is a warning [*Prescription*] in the source document [*Patent*].

Rivaroxaban ↔ Verapamil hydrochloride

Interaction

General information   Prescription: ● Warning/Precaution

Prescribing Details

Dose adjustment would be needed
Dose adjustment would be needed. Higher risk of bleeding is expected in patients with renal failure than in normal renal function.

Evaluated Entity   Rivaroxaban   Evaluated Entity Type   Product

Related Content

🛡	Drugs & Biologics	2
🧬	Genes & Targets	2
🧪	Pharmacokinetics	103
📄	Patents	1

Interaction Details

Interacting Entity	Interacting Entity Type	Interaction Type	Protein/Action	Strength
Verapamil hydrochloride	Product	Pharmacokinetics (ADME)	ATP-dependent translocase ABCB1 isoform 1 | Inhibition	
			Cytochrome P450 3A4 (isoform 1) | Inhibition	

Outcome information

Population	Humans/Fed
Outcome	Increased Pharmacokinetic Exposure (Adverse Event/Toxicity)
Available Since	Dec 16, 2020

Outcome Validity   Supported by Experiments

Adverse Events   Bleeding

> Go to associated **Pharmacokinetics** records to compare all experiments from the same source. both alone and in co-administration.

For more information contact Customer Service at **LS Product Support.**